Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as alemtuzumab and rituximab, can kill chronic
lymphocytic leukemia (CLL) cells and are effective therapies for this disease. Biological
therapies, such as Imprime PGG (poly-(1-6)-beta-glucotriosyl-(1-3)-beta-glucopyranose), may
stimulate the immune system in different ways and help monoclonal antibodies kill CLL cells.
Giving PGG beta-glucan together with alemtuzumab and rituximab could make therapy with
monoclonal antibodies, such as alemtuzumab and rituximab, more effective.
PURPOSE: This phase I/II trial is studying the side effects and best dose of PGG beta-glucan
when given together with alemtuzumab and rituximab and to see how well it works in treating
patients with earlier stage high-risk chronic lymphocytic leukemia.